PMID- 25385737
OWN - NLM
STAT- MEDLINE
DCOM- 20150223
LR  - 20210103
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 32
IP  - 36
DP  - 2014 Dec 20
TI  - Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows 
      hematologic and molecular remissions in patients with relapsed or refractory 
      B-precursor acute lymphoblastic leukemia.
PG  - 4134-40
LID - 10.1200/JCO.2014.56.3247 [doi]
AB  - PURPOSE: Patients with relapsed or refractory acute lymphoblastic leukemia (ALL) 
      have a dismal prognosis. CD19 is homogenously expressed in B-precursor ALL and 
      can be targeted by the investigational bispecific T cell-engager antibody 
      blinatumomab. A phase II trial was performed to determine clinical activity in 
      this patient cohort. PATIENTS AND METHODS: Thirty-six patients with relapsed or 
      refractory B-precursor ALL were treated with blinatumomab in cycles of 4-week 
      continuous infusion followed by a 2-week treatment-free interval in a single-arm 
      study with a dose-finding stage and an extension stage. The primary end point was 
      complete remission (CR) or CR with partial hematologic recovery (CRh). Major 
      secondary end points included minimal residual disease (MRD) response, rate of 
      allogeneic hematopoietic stem-cell transplantation (HSCT) realization, 
      relapse-free survival (RFS), overall survival (OS), and incidence of adverse 
      events (AEs). RESULTS: Median age was 32 years (range, 18 to 77 years). 
      Twenty-five patients (69%) achieved a CR or CRh, with 88% of the responders 
      achieving an MRD response. Median OS was 9.8 months (95% CI, 8.5 to 14.9), and 
      median RFS was 7.6 months (95% CI, 4.5 to 9.5). Thirteen responders (52%) 
      underwent HSCT after achieving a CR or CRh. The most frequent AE during treatment 
      was pyrexia (grade 1 or 2, 75%; grade 3, 6%). In six patients with nervous system 
      or psychiatric disorder AEs and in two patients with cytokine release syndrome, 
      treatment had to be interrupted or discontinued. These medical events were 
      resolved clinically. CONCLUSION: The data support further investigation of 
      blinatumomab for the treatment of adult patients with relapsed or refractory ALL 
      in a larger confirmatory study.
CI  - (c) 2014 by American Society of Clinical Oncology.
FAU - Topp, Max S
AU  - Topp MS
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD. 
      topp_m@ukw.de.
FAU - Gokbuget, Nicola
AU  - Gokbuget N
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Zugmaier, Gerhard
AU  - Zugmaier G
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Klappers, Petra
AU  - Klappers P
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Stelljes, Matthias
AU  - Stelljes M
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Neumann, Svenja
AU  - Neumann S
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Viardot, Andreas
AU  - Viardot A
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Marks, Reinhard
AU  - Marks R
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Diedrich, Helmut
AU  - Diedrich H
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Faul, Christoph
AU  - Faul C
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Reichle, Albrecht
AU  - Reichle A
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Horst, Heinz-August
AU  - Horst HA
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Bruggemann, Monika
AU  - Bruggemann M
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Wessiepe, Dorothea
AU  - Wessiepe D
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Holland, Chris
AU  - Holland C
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Alekar, Shilpa
AU  - Alekar S
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Mergen, Noemi
AU  - Mergen N
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Einsele, Hermann
AU  - Einsele H
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Hoelzer, Dieter
AU  - Hoelzer D
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
FAU - Bargou, Ralf C
AU  - Bargou RC
AD  - Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Universitatsklinikum Wurzburg, 
      Wurzburg; Nicola Gokbuget, Goethe University; Dieter Hoelzer, Onkologikum, 
      Frankfurt; Gerhard Zugmaier, Petra Klappers, and Noemi Mergen, Amgen Research; 
      Dorothea Wessiepe, Metronomia, Munich; Matthias Stelljes, University of Munster, 
      Munster; Svenja Neumann, Heinz-August Horst, and Monika Bruggemann, University 
      Schleswig Holstein, City Hospital, Kiel; Andreas Viardot, University of Ulm, Ulm; 
      Reinhard Marks, Universitatsklinikum Freiburg, Freiburg; Helmut Diedrich, 
      Medizinische Hochschule Hannover, Hannover; Christoph Faul, Universitatsklinikum 
      Tubingen, Tubingen; Albrecht Reichle, Universitatsklinikum Regensburg, 
      Regensburg, Germany; and Chris Holland and Shilpa Alekar, Amgen, Rockville, MD.
LA  - eng
SI  - ClinicalTrials.gov/NCT01209286
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20141110
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antibodies, Bispecific)
RN  - 4FR53SIF3A (blinatumomab)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibodies, Bispecific/adverse effects/*therapeutic use
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm, Residual
MH  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/blood/*drug therapy/mortality
MH  - Recurrence
MH  - Remission Induction
EDAT- 2014/11/12 06:00
MHDA- 2015/02/24 06:00
CRDT- 2014/11/12 06:00
PHST- 2014/11/12 06:00 [entrez]
PHST- 2014/11/12 06:00 [pubmed]
PHST- 2015/02/24 06:00 [medline]
AID - JCO.2014.56.3247 [pii]
AID - 10.1200/JCO.2014.56.3247 [doi]
PST - ppublish
SO  - J Clin Oncol. 2014 Dec 20;32(36):4134-40. doi: 10.1200/JCO.2014.56.3247. Epub 
      2014 Nov 10.